Physician profile
Michael Bentley
NPI 1063472322
$5,400.40
in general payments reported to CMS, 2019-2025
18 companies · $523 in 2025
The $523 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $643 · 2021: $696 · 2022: $385 · 2023: $952 · 2024: $666 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112 · Education: $28.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.69 |
| Education | $28.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,026.61 | 2019-2022 | |
| Abbvie INC. | $1,571.64 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Mentor Worldwide LLC | $622.64 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Merz North America, INC. | $467.12 | 2019-2024 | Xeomin |
| Sientra, INC. | $205.20 | 2019-2021 | |
| Integra Lifesciences Corporation | $183.23 | 2020-2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Regeneron Healthcare Solutions, INC. | $113.27 | 2023-2024 | Libtayo |
| Vertex Pharmaceuticals Incorporated | $44.00 | 2024-2025 | |
| Tela Bio, INC. | $34.12 | 2021-2024 | Ovitex 2s |
| Motiva USA, LLC | $21.72 | 2025 | |
| Revance Therapeutics, INC. | $20.42 | 2024 | Daxxify |
| Mimedx Group, INC. | $18.51 | 2024 | |
| Tei Biosciences INC | $16.69 | 2019 | |
| Avanos Medical | $15.08 | 2019 | |
| Galderma Laboratories, L.P. | $14.69 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $13.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.98 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.